Drug Trial Radar · NCT07469228
A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,043
Actual
Start
Aug 4, 2025
Primary completion
Dec 15, 2025
Study completion Dec 15, 2025
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To demonstrate the efficacy, therapeutic equivalence and safety of tretinoin gel microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (tretinoin) gel microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
Tretinoin Gel Microsphere, 0.04%Drug
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%Drug
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Placebo ControlDrug
The investigational product will be applied topically to the affected areas of the face lightly once daily at bedtime, avoiding the eyes, mouth, and other mucous membranes for 84 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate & evaluate the therapeutic, equivalence and safety of the investigational productTime frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Pharmaceutical Industries, Inc.
Hawthorne, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.